CL2020002444A1 - Usos de un inhibidor de masp-2 para proteger un riñón de nefropatía fármaco-inducida (divisional de la solicitud no. 201801817) - Google Patents

Usos de un inhibidor de masp-2 para proteger un riñón de nefropatía fármaco-inducida (divisional de la solicitud no. 201801817)

Info

Publication number
CL2020002444A1
CL2020002444A1 CL2020002444A CL2020002444A CL2020002444A1 CL 2020002444 A1 CL2020002444 A1 CL 2020002444A1 CL 2020002444 A CL2020002444 A CL 2020002444A CL 2020002444 A CL2020002444 A CL 2020002444A CL 2020002444 A1 CL2020002444 A1 CL 2020002444A1
Authority
CL
Chile
Prior art keywords
masp
kidney
inhibitor
drug
protect
Prior art date
Application number
CL2020002444A
Other languages
English (en)
Inventor
Gregory A Demopulos
Thomas Dudler
Hans-Wilhelm Schwaeble
Nigel John Brunskill
Original Assignee
Omeros Corp
Univ Leicester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Omeros Corp, Univ Leicester filed Critical Omeros Corp
Publication of CL2020002444A1 publication Critical patent/CL2020002444A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

En un aspecto, la invención proporciona usos de un inhibidor de MASP-2 para proteger un riñón de nefropatía fármaco-inducida en un sujeto que ha experimentado, está experimentando, o va a someterse a tratamiento con uno o más agentes nefrotóxicos.
CL2020002444A 2016-01-05 2020-09-23 Usos de un inhibidor de masp-2 para proteger un riñón de nefropatía fármaco-inducida (divisional de la solicitud no. 201801817) CL2020002444A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662275025P 2016-01-05 2016-01-05
US201662407979P 2016-10-13 2016-10-13

Publications (1)

Publication Number Publication Date
CL2020002444A1 true CL2020002444A1 (es) 2021-02-19

Family

ID=59236184

Family Applications (3)

Application Number Title Priority Date Filing Date
CL2018001817A CL2018001817A1 (es) 2016-01-05 2018-07-03 Métodos para la inhibición de la fibrosis en un sujeto en necesidad de ellos
CL2019001411A CL2019001411A1 (es) 2016-01-05 2019-05-24 Métodos para inhibición de la fibrosis en un sujeto en necesidad de ellos. (divisional solicitud 201801817)
CL2020002444A CL2020002444A1 (es) 2016-01-05 2020-09-23 Usos de un inhibidor de masp-2 para proteger un riñón de nefropatía fármaco-inducida (divisional de la solicitud no. 201801817)

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CL2018001817A CL2018001817A1 (es) 2016-01-05 2018-07-03 Métodos para la inhibición de la fibrosis en un sujeto en necesidad de ellos
CL2019001411A CL2019001411A1 (es) 2016-01-05 2019-05-24 Métodos para inhibición de la fibrosis en un sujeto en necesidad de ellos. (divisional solicitud 201801817)

Country Status (20)

Country Link
US (3) US10736960B2 (es)
EP (1) EP3400012A4 (es)
JP (3) JP6682653B2 (es)
KR (4) KR102564616B1 (es)
CN (3) CN117503923A (es)
AU (4) AU2017205453B2 (es)
CA (2) CA3185172A1 (es)
CL (3) CL2018001817A1 (es)
EA (1) EA201891570A1 (es)
GE (2) GEP20217290B (es)
IL (3) IL320282A (es)
MA (1) MA43591A (es)
MX (3) MX2018008331A (es)
MY (1) MY194810A (es)
NZ (1) NZ744629A (es)
PH (1) PH12018501435A1 (es)
SG (2) SG11201805695SA (es)
UA (1) UA127339C2 (es)
WO (1) WO2017120344A1 (es)
ZA (1) ZA201805238B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101141544B1 (ko) 2009-03-13 2012-05-03 한국과학기술원 에스아이알엔에이 다중 접합체 및 이의 제조방법
IL316159A (en) 2015-06-15 2024-12-01 Mpeg La Llc Defined Oligonucleotide Multimers and Methods for Manufacture Thereof
SG11201805695SA (en) 2016-01-05 2018-07-30 Univ Leicester Methods for inhibiting fibrosis in a subject in need thereof
JOP20170170B1 (ar) 2016-08-31 2022-09-15 Omeros Corp صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق
JOP20190068B1 (ar) * 2016-10-13 2024-12-22 Omeros Corp طرق لتقليل البول البروتيني في خاضع بشري يعاني من الاعتلال الكلوي a الناتج عن الجلوبيولين المناعي
EP3576752A4 (en) 2017-02-06 2020-12-16 Mpeg La, LLC MULTIMERIC OLIGONUCLEOTIDES WITH REDUCED RENAL CLEARANCE
BR112020003737A2 (pt) * 2017-08-31 2020-09-01 Novartis Ag usos de derivados de piperidinil-indol
CN111971297A (zh) * 2018-05-16 2020-11-20 韩国亿诺生物有限公司 包含lrit2抑制剂作为活性成分用于预防或治疗癌症的药物组合物
CN118373875A (zh) 2018-05-29 2024-07-23 奥默罗斯公司 Masp-2抑制剂和使用方法
WO2020186256A1 (en) * 2019-03-14 2020-09-17 Aravive Inc Methods of treating immunoglobulin a nephropathy (igan) using axl decoy receptors
WO2021026476A1 (en) * 2019-08-08 2021-02-11 Mpeg La, L.L.C. Complement targeting with multimeric oligonucleotides
KR20220104201A (ko) * 2019-11-26 2022-07-26 오메로스 코포레이션 조혈 줄기 세포 이식과 관련된 특발성 폐렴 증후군 (ips) 및/또는 모세혈관 누출 증후군 (cls) 및/또는 생착 증후군 (es) 및/또는 체액 과부하 (fo)를 치료 및/또는 예방하는 방법
KR20220110531A (ko) 2019-12-04 2022-08-08 오메로스 코포레이션 Masp-2 억제자 및 사용 방법
WO2021113698A1 (en) 2019-12-04 2021-06-10 Omeros Corporation Masp-2 inhibitors and methods of use
WO2021113682A1 (en) 2019-12-04 2021-06-10 Omeros Corporation Masp-2 inhibitors and methods of use
KR20220110529A (ko) 2019-12-04 2022-08-08 오메로스 코포레이션 Masp-2 억제자 및 사용 방법
KR20230015874A (ko) 2019-12-17 2023-01-31 치누크 세라퓨틱스, 인크. 아트라센탄에 의해 iga 신장병증을 치료하는 방법
CN111419860A (zh) * 2020-03-19 2020-07-17 长春市儿童医院 一种肾小球分叶状肾病造模方法
JP7826221B2 (ja) 2020-04-30 2026-03-09 エムペグ エルエイ リミテッド ライアビリティ カンパニー 分割鎖を有する多量体オリゴヌクレオチド
US12263144B2 (en) * 2020-10-13 2025-04-01 Accubit LLC—Biotechnology Methods of treating IgA nephropathy with thiol-containing molecules
CN120173119B (zh) * 2020-12-16 2025-09-30 康诺亚生物医药科技（成都）有限公司 一种补体抑制剂的开发和应用
EP4353749A4 (en) * 2021-06-08 2025-07-16 Shanghai Jemincare Pharmaceuticals Co Ltd ANTI-MASP-2 ANTIBODY AND ITS USE
WO2023103789A1 (zh) * 2021-12-10 2023-06-15 舒泰神（北京）生物制药股份有限公司 特异性识别masp2的抗体及其应用
PY22106817A (es) 2021-12-10 2023-12-21 Omeros Corp Anticuerpos terapéuticos que se unen al dominio serina-proteasa de masp-2 y usos de estos
WO2023173036A2 (en) 2022-03-10 2023-09-14 Omeros Corporation Masp-2 and masp-3 inhibitors, and related compositions and methods, for treatment of sickle cell disease
US20250352511A1 (en) * 2022-05-19 2025-11-20 Chinook Therapeutics, Inc. Methods of treating focal segmental glomerulosclerosis with atrasentan
JP2025541737A (ja) 2022-11-30 2025-12-23 オメロス コーポレーション Ｍａｓｐ－２阻害物質としての縮合ピリミジン
WO2025076476A2 (en) 2023-10-06 2025-04-10 Omeros Corporation Masp-2 inhibitors and methods of use

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5453566A (en) 1986-03-28 1995-09-26 Calgene, Inc. Antisense regulation of gene expression in plant/cells
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
AU632993B2 (en) 1987-12-15 1993-01-21 Gene Shears Pty. Limited Ribozymes
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8822492D0 (en) 1988-09-24 1988-10-26 Considine J Apparatus for removing tumours from hollow organs of body
US5211657A (en) 1988-11-07 1993-05-18 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
SG46445A1 (en) 1990-01-26 1998-02-20 Immunomedics Inc Vaccines against cancer and infectious diseases
JP3218637B2 (ja) 1990-07-26 2001-10-15 大正製薬株式会社 安定なリポソーム水懸濁液
US5789573A (en) 1990-08-14 1998-08-04 Isis Pharmaceuticals, Inc. Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2
JP2958076B2 (ja) 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
IL108367A0 (en) 1993-01-27 1994-04-12 Hektoen Inst For Medical Resea Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells
US5801154A (en) 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
US5741516A (en) 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
US5739119A (en) 1996-11-15 1998-04-14 Galli; Rachel L. Antisense oligonucleotides specific for the muscarinic type 2 acetylcholine receptor MRNA
US6649592B1 (en) 2000-01-14 2003-11-18 Science & Technology Corporation @ Unm Peptide inhibitors of LFA-1/ICAM-1 interaction
SG98393A1 (en) 2000-05-19 2003-09-19 Inst Materials Research & Eng Injectable drug delivery systems with cyclodextrin-polymer based hydrogels
CA2490007C (en) 2002-07-19 2011-05-24 Omeros Corporation Biodegradable triblock copolymers, synthesis methods therefor, and hydrogels and biomaterials made there from
CN1798769A (zh) 2003-05-12 2006-07-05 内蒂穆恩公司 抗masp－2抗体
US7919094B2 (en) 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US8840893B2 (en) 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US20140056873A1 (en) * 2004-06-10 2014-02-27 University Of Leicester Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
US7626730B2 (en) * 2006-03-31 2009-12-01 Eastman Kodak Company Method of making a multilevel halftone screen
AU2010306581B2 (en) 2009-10-16 2015-03-19 Omeros Corporation Methods for treating disseminated intravascular coagulation by inhibiting MASP-2 dependent complement activation
US9102721B2 (en) 2011-01-21 2015-08-11 Fibrogen, Inc. Therapeutic method
US9644035B2 (en) * 2011-04-08 2017-05-09 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
CN107638565B (zh) 2011-04-08 2021-12-21 莱斯特大学 用于治疗与masp-2依赖性补体活化相关的状况的方法
MX361175B (es) * 2011-05-04 2018-11-29 Omeros Corp Composiciones para inhibir la activación del complemento dependiente de la masp-2.
EP2861246B1 (en) * 2012-06-18 2021-01-20 Omeros Corporation Compositions and methods of inhibiting masp-1 and/or masp-2 and/or masp-3 for the treatment of various diseases and disorders
AU2014229020B2 (en) 2013-03-15 2017-09-28 Omeros Corporation Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same
RS61351B1 (sr) 2013-10-17 2021-02-26 Omeros Corp Postupci za lečenje stanja udruženih sa aktivacijom komplementa zavisnom od masp-2
SG11201805695SA (en) 2016-01-05 2018-07-30 Univ Leicester Methods for inhibiting fibrosis in a subject in need thereof
JOP20170170B1 (ar) * 2016-08-31 2022-09-15 Omeros Corp صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق
US20180105604A1 (en) 2016-10-13 2018-04-19 University Of Leicester Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathy
KR101930345B1 (ko) * 2016-12-20 2019-03-11 김은진 지혈제 조성물

Also Published As

Publication number Publication date
CL2018001817A1 (es) 2019-01-11
CN117503923A (zh) 2024-02-06
NZ783304A (en) 2025-05-02
ZA201805238B (en) 2023-05-31
KR102528260B1 (ko) 2023-05-04
JP2019504880A (ja) 2019-02-21
US10736960B2 (en) 2020-08-11
KR102780411B1 (ko) 2025-03-12
AU2022203914A1 (en) 2022-06-23
NZ744629A (en) 2020-06-26
US20170189525A1 (en) 2017-07-06
AU2022203914B2 (en) 2025-05-01
MX2024010937A (es) 2024-09-17
AU2020201804A1 (en) 2020-03-26
KR102564616B1 (ko) 2023-08-08
CA3185172A1 (en) 2017-07-13
UA127339C2 (uk) 2023-07-26
IL260430B2 (en) 2023-06-01
AU2017205453B2 (en) 2020-03-12
MA43591A (fr) 2021-05-26
MY194810A (en) 2022-12-16
JP6682653B2 (ja) 2020-04-15
CA3010593C (en) 2024-02-13
JP7430208B2 (ja) 2024-02-09
GEAP202114848A (en) 2021-05-13
IL294411A (en) 2022-08-01
US20210077621A1 (en) 2021-03-18
KR20200116175A (ko) 2020-10-08
JP2022065145A (ja) 2022-04-26
PH12018501435A1 (en) 2019-03-04
IL294411B2 (en) 2025-10-01
US20240424091A1 (en) 2024-12-26
JP2020114845A (ja) 2020-07-30
IL294411B1 (en) 2025-06-01
CL2019001411A1 (es) 2019-08-02
BR112018013723A2 (pt) 2018-12-26
US12005117B2 (en) 2024-06-11
MX2018008331A (es) 2019-05-30
KR20180096794A (ko) 2018-08-29
NZ760818A (en) 2025-03-28
WO2017120344A1 (en) 2017-07-13
AU2022221419B2 (en) 2025-04-24
IL260430A (es) 2018-08-30
AU2020201804B2 (en) 2022-06-16
IL320282A (en) 2025-06-01
EA201891570A1 (ru) 2018-12-28
SG11201805695SA (en) 2018-07-30
CA3010593A1 (en) 2017-07-13
AU2022221419A1 (en) 2022-11-10
EP3400012A4 (en) 2019-12-11
MX2023007754A (es) 2023-07-07
AU2017205453A1 (en) 2018-08-16
KR20230080493A (ko) 2023-06-07
CN114306593A (zh) 2022-04-12
GEP20217290B (en) 2021-09-10
IL260430B1 (es) 2023-02-01
SG10202001580SA (en) 2020-04-29
KR20220011791A (ko) 2022-01-28
KR102475622B1 (ko) 2022-12-08
EP3400012A1 (en) 2018-11-14
CN108495652A (zh) 2018-09-04

Similar Documents

Publication Publication Date Title
CL2021000039A1 (es) Moléculas de anticuerpo que se unen a cd73 y usos de las mismas (divisional solicitud 201903796)
CL2021000343A1 (es) Inhibidores peptídicos del receptor de interleucina 23 (divisional de la solicitud n° 201800128)
CL2018001790A1 (es) Procesos para preparar un inhibidor de jak1 y nuevas formas de este (divisional solicitud 201602748)
UY37391A (es) Formulaciones de anticuerpos inhibidores de masp-2 de baja viscosidad y altamente concentradas, kits, y métodos
CR20190350A (es) INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS
CR20200290A (es) PÉPTIDOS Y COMPOSICIONES PARA EL TRATAMIENTO DE DAÑO ARTICULAR (Divisional 2015-0466)
MX384792B (es) Inhibidores de desmetilasa especifica de lisina 1 (lsd1).
CR20190105A (es) Composiciones y métodos de inhibir masp-3 para el tratamiento de diversas enfermedades y trastornos
UY37381A (es) Compuestos que inhiben proteasas 3c y 3cl y métodos de uso de los mismos
MX2023001193A (es) Composicion de un anticuerpo inhibidor de masp-2 para usarse en el tratamiento de un padecimiento asociado con la activacion del complemento dependiente de masp-2.
CR20160132A (es) Composiciones y método para tratar condiciones asociadas con el complemento
CL2018000596A1 (es) Nuevos compuestos bicíclicos como inhibidores de la atx
CO2021004141A2 (es) Moduladores de la expresión de pnpla3
MX2016010237A (es) Metodos de tratamiento de enfermedad de alzheimer.
BR112015023207A2 (pt) uso de c1-inh no tratamento de desordens associadas à deficiência de inibidor de c1 esterase
MX2022006817A (es) Formulaciones/composiciones que comprenden un inhibidor de btk.
CO2019011265A2 (es) Moduladores de la expresión de pcsk9
MX389367B (es) Composiciones farmaceuticas liquidas que comprenden inhibidores de sglt-2.
EA201891440A1 (ru) Составы/композиции, содержащие ингибитор btk
MX2020003270A (es) Combinacion de un inhibidor de btk y un inhibidor de cdk9 para tratar el cancer.
TW201625535A (en) Inhibitors of histone demethylases
MX2020012497A (es) Moduladores de la expresion de apol1.
EA201792641A1 (ru) Ингибитор оси igfbp3/tmem219 и диабет
MX2017007000A (es) Composiciones que comprenden acido 15-hidroxieicosapentaenoico (15-hepe) y metodos para tratar o prevenir la fibrosis usando las mismas.
MX2021000542A (es) Apirasas solubilizadas, metodos y usos.